Ascentage Pharma Group International
AAPGNASDAQHealthcareBiotechnology
前收盘价
US$17.00
−US$0.32 · -1.85%
AAPG公司概览
盘中时间采用ET。市场数据可能有所延迟。
GoAI 研究快照
简明呈现最新可用的模型信息。
GoAI评分
Sell
Trim exposure — unfavorable risk-reward
估值
37
Expensive
动量
28
Weakening
情绪
57
Mixed
风险韧性
37
High Risk
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
人工智能生成的上下文仅供参考，并非投资建议。
公司概况
公司网站Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation. The company's portfolio also encompasses APG-2575, an orally administered, selective Bcl-2 inhibitor aimed at treating hematologic malignancies and solid tumors. Another key asset, APG-115, is an oral small molecule that intervenes in MDM2-p53 protein-protein interactions, showing potential for both solid and blood cancers. Further bolstering its oncology efforts is APG-1252, a small molecule therapy engineered to reactivate programmed cell death (apoptosis) by dually inhibiting Bcl-2 and Bcl-xL proteins, targeting diseases such as small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. Beyond these, Ascentage is actively developing APG-1387, a small molecule apoptosis inhibitor designated for advanced solid tumors and chronic HBV. Its pipeline also features APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, a selective, orally available embryonic ectoderm development inhibitor; APG-265, an MDM2 protein degrader; and UBX1967/1325, which are additional Bcl-2 inhibitors. In addition to its core pharmaceutical activities, the company engages in medical research, clinical trial operations, venture capital investments, and offers rental and technology promotion services. Ascentage Pharma also cultivates strategic partnerships with various biotechnology and pharmaceutical companies, alongside research institutions. The company was founded in 2009.
- 行业
- Biotechnology
- 部门
- Healthcare
- 总部
- CN
- 首席执行官
- Dajun Yang
- 上市以来
- 2025年1月24日
- 雇员
- 767
市场位置
日内区间
当前US$17.00，
52周区间
当前US$17.00，
- 开盘价
- US$17.20
- 前收盘价
- US$17.32
- 成交量
- 1733
- 0.18× 平均值
- 平均成交量
- 9446
- 日均成交量
- 市值
- 15.8亿 USD
- 贝塔
- 0.66
- 市场参考 1
- 50天平均值
- US$18.1851
- 低于平均水平-6.52%
- 200天平均值
- US$23.6338
- 低于平均水平-28.07%
财务数据
财务快照
最近十二个月估值与收益率
- 企业价值
- 158.46亿 CNY
- 市盈率（TTM）
- -7.31×
- 市净率（TTM）
- 19.13×
- 市销率（TTM）
- 16.75×
- EV/EBITDA
- -14.47×
- 盈利收益率
- -7.40%
- 自由现金流收益率
- -7.36%
- 股息率
- 0.00%
盈利能力和效率
- 毛利率
- 81.56%
- 营业利润率
- -218.76%
- 净利润率
- -228.69%
- 净资产收益率
- -91.22%
- 资产收益率
- -30.48%
- 投入资本回报率
- -33.26%
财务健康
- 负债权益比
- 3.76×
- 流动比率
- 1.79×
财务报表
利润率趋势
盈利能力占已公布营收的百分比。
损益趋势
营收
营业利润
净利润
| 项目（CNY） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 5.58亿 CNY | 9.81亿 CNY | 2.22亿 CNY | 2.1亿 CNY | 2791万 CNY |
| 销货成本 | 1.32亿 CNY | 2908.5万 CNY | 3054.3万 CNY | 2199.8万 CNY | 332.8万 CNY |
| 毛利 | 4.27亿 CNY | 9.52亿 CNY | 1.91亿 CNY | 1.88亿 CNY | 2458.2万 CNY |
| 研究与开发 | 10.83亿 CNY | 9.47亿 CNY | 7.07亿 CNY | 7.43亿 CNY | 7.66亿 CNY |
| 销售、一般及管理费用 | 5.23亿 CNY | 3.83亿 CNY | 3.76亿 CNY | 3.28亿 CNY | 1.91亿 CNY |
| 营业费用 | 16.06亿 CNY | 13.21亿 CNY | 10.64亿 CNY | 10.38亿 CNY | 9.58亿 CNY |
| 利息收入 | 7988.75万 CNY | 3784万 CNY | 3240.9万 CNY | 972.7万 CNY | 710.6万 CNY |
| 利息支出 | 5259.69万 CNY | 6445.5万 CNY | 9605.7万 CNY | 5278.5万 CNY | 1673.1万 CNY |
| 折旧和摊销 | 8412.39万 CNY | 9316.9万 CNY | 9319.5万 CNY | 4742.1万 CNY | 1718.3万 CNY |
| 营业利润 | −11.79亿 CNY | −3.7亿 CNY | −8.73亿 CNY | −8.5亿 CNY | −8.7亿 CNY |
| 净利润 | −12.09亿 CNY | −4.05亿 CNY | −9.26亿 CNY | −8.83亿 CNY | −7.82亿 CNY |
公司数据更新于 2026年8月24日。
AAPG 消息
AAPG同业公司
继续GoAI的研究
在 GoAI 中研究AAPGresearch.disclaimer